Vitamin K2 (60 µg MK-7) is Safe for Elderly CKD Stage 3b-4 Patients
Yes, 60 µg daily of vitamin K2 (menaquinone-7) is safe for an elderly patient with CKD stage 3b-4, provided they are not taking warfarin or other vitamin K antagonist anticoagulants.
Key Safety Considerations
Anticoagulant Use is the Primary Contraindication
The 2020 KDOQI nutrition guideline explicitly states that patients receiving anticoagulant medicines that inhibit vitamin K activity (e.g., warfarin) should not receive vitamin K supplements 1. This is the only absolute contraindication mentioned in current guidelines.
- If your patient is on warfarin → Do not give vitamin K2
- If on DOACs (apixaban, rivaroxaban, etc.) → Safe to proceed (these do not interact with vitamin K)
- If on no anticoagulants → Safe to proceed
Safety Evidence in CKD Populations
The dose you're asking about (60 µg) is well below the doses studied in CKD patients:
- The K4Kidneys trial used 400 µg daily of MK-7 in CKD stage 3b-4 patients for 12 months with no safety concerns 2
- A recent dialysis study used 360 µg daily for 52 weeks and found no detectable coagulation activation, no increase in vascular events, and no difference in serious adverse events compared to placebo 3
- The 2025 KDIGO guideline review references multiple trials using 360-400 µg MK-7 in CKD patients without safety issues 4
Your proposed 60 µg dose is approximately 6-fold lower than these well-tolerated doses.
General Safety Profile
A comprehensive US Pharmacopeial Convention safety review concluded that menaquinone-7 as a dietary supplement is not associated with any serious risk to health 5. The typical supplemental doses range from 45-360 µg daily, and your 60 µg dose falls at the lower end of this spectrum.
Efficacy Considerations (Though Not Your Primary Question)
While safety is established, it's worth noting that efficacy data are mixed:
- The K4Kidneys trial (400 µg MK-7 in CKD 3b-4) showed no benefit for vascular stiffness or calcification progression 2
- However, a 2026 trial in coronary artery disease patients found that 360 µg MK-7 significantly slowed calcification progression over 2 years 6
- Studies consistently show MK-7 supplementation improves vitamin K status biomarkers (reduces dp-ucMGP and PIVKA-II) even if clinical outcomes remain uncertain 7, 8, 9
Practical Recommendation
Proceed with 60 µg daily MK-7 supplementation if:
- Patient is NOT on warfarin
- You document baseline vitamin K status if possible (though not required)
- You monitor for any unexpected bleeding (theoretical concern, though not observed in trials)
Do not supplement if:
- Patient is on warfarin or other vitamin K antagonists 1
The dose is conservative, well within established safety margins, and poses minimal risk in this population based on current evidence.